Asset

BATOCLIMAB

Immunovant Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (4)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT03863080phase2completed2019-05-212020-10-07Immunovant Sciences GmbHA Study of RVT-1401 in Myasthenia Gravis (MG) Patients
NCT03938545phase2terminated2019-07-232021-02-02Immunovant Sciences GmbHASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )
NCT03922321phase2completed2019-04-222020-02-29Immunovant Sciences GmbHStudy of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)
NCT04253236phase2terminated2020-08-112021-04-01Immunovant Sciences GmbHTo Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)